| Literature DB >> 34907291 |
Xiaozheng Wu1, Wen Li1, Zhenliang Luo1, Yunzhi Chen2.
Abstract
MUC5B promoter rs35705950 T/G gene polymorphism has been associated with the risk of IPF, but the influence of this relationship varies among different populations. In the past 2 years, there were new clinical studies with different results, but none of them reached unified conclusions. Therefore, this study further included the latest case-control studies, integrated their results and carried out meta-analysis on them to draw reliable conclusions. PubMed, EMBASE, CNKI, Wanfang database and VIP Chinese science were searched by a computer to collect the related literatures of MUC5B gene polymorphism and IPF susceptibility published before June 15, 2021. The first author, year of publication, diagnostic criteria and gene frequency were extracted after screened them. Forest plot was drawn and the trial sequential analysis (TSA) was carried out to confirm the stability of the meta-analysis results. Registration number: CRD42021272940. A total of 24 case-control studies (13 studies on the Caucasian, 7 studies on the Asian and 4 studies on the mixed population), and a total of 6749 IPF patients and 13,898 healthy controls were included in this study. The T vs.G, TT vs. GG, GT vs. GG, GT + TT vs. GG and TT vs. GG + GT genetic models of MUC5B promoter rs35705950 T/G polymorphism were associated with IPF risk in all populations, and the effect values were ([OR] 4.12, 95% CI [3.64, 4.67]), ([OR] 10.12, 95% CI [7.06, 14.49]), ([OR] 4.84, 95% CI [3.85, 6.08]), ([OR] 4.84, 95% CI [3.79, 6.19]) and ([OR] 5.11, 95% CI [4.02, 6.49]), respectively. The results of TSA confirmed the stability of the results. Subgroup analysis showed that T vs.G, TT vs. GG, GT vs. GG, GT + TT vs. GG and TT vs. GG + GT genetic models of MUC5B polymorphism were associated with IPF risk in Caucasian population. The effect values were ([OR] 4.50, 95% CI [3.93, 5.16]), ([OR] 10.98, 95% CI [7.59, 15.89]), ([OR] 6.27, 95% CI [5.37, 7.32]), ([OR] 6.30, 95% CI [5.19, 7.64]) and ([OR] 5.15, 95% CI [4.01, 6.61]), respectively. Similar results were also found in Asian and mixed populations. The association strength of the minor T allele in the Caucasian was more significant than that of the Asian population ([OR] 4.50 vs. [OR] 2.39), and the association strength of all genetic models carrying "T" was more significant than that of the Asian population ([OR] 10.98 vs. [OR] 4.29). In Caucasian, Asian and mixed populations, T minor allele carriers were more likely to be susceptible to pulmonary fibrosis, and TT genotype carriers were more likely to be susceptible to IPF than GT genotype carriers. The association between IPF and Caucasian population with minor T allele and all "T" genetic model was more significant than that of Asian population.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34907291 PMCID: PMC8671516 DOI: 10.1038/s41598-021-03533-z
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1PRISMA literature screening flow chart.
Basic features of the included study.
| Studies | Year | Country | Ethnicity | Diagnostic criteria | Cases(N) | Gender (male/female)(N) | Age (years) | Genotyping method | HWE | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPF | Control | IPF | Control | IPF | Control | |||||||
| Allen[ | 2017 | UK | Caucasian | 2011,2015ATS/ERS/JRS/ALAT consensus statement | 602 | 3366 | 426/176 | 2356 /1010 | 70 ± 8.4 | 65 ± 5.5 | Affymetrix Axiom UK BiLEVE array | Yes |
| Bonella[ | 2021 | Germany | Caucasian | 2011,2018 ATS/ERS/JRS/ALAT consensus statement | 62 | 50 | 43/8 | 37/13 | 63.5 ± 11 | 42 ± 2 | TaqMan SNP Genotyping Assay | Yes |
| Borie[ | 2013 | France | Caucasian | 2001 ATS/ERS consensus statement | 142 | 1383 | 116/26 | – | 69.86 ± 8.9 | – | Taqman SNP genotyping assay-allelic discrimination method | Yes |
| Deng[ | 2018 | China | Asian | 2011 ATS/ERS/JRS/ALAT consensus statement | 253 | 125 | 169/84 | 41/84 | 65.4 ± 11.1 | 65.3 ± 10.8 | PCR | Yes |
| Dressen[ | 2018 | USA | Caucasian | 2011 ATS/ERS/JRS/ALAT consensus statement | 1510 | 1874 | 1119/391 | 507/1367 | 67.29 ± 7.98 | 56.38 ± 9.32 | Illumina X10 sequencers | Yes |
| Gou[ | 2020 | China | Asian | 2011 ATS/ERS/JRS/ALAT consensus statement | 88 | 88 | 53/35 | 53/35 | 66.92 ± 5.80 | 66.30 ± 6.06 | PCR | Yes |
| Helling[ | 2017 | USA | Mixed | 2013 ATS/ERS consensus statement | 203 | 139 | 124/79 | 69/70 | 64 ± 8.3 | 57 ± 14.5 | Taqman gene expression assay | Yes |
| HORIMASU (Asian)[ | 2014 | Japanese | Asian | 2002 ATS/ERS consensus statement | 44 | 310 | 35/9 | 255/55 | 67.5 ± 1.6 | 50.6 ± 0.4 | TaqMan SNP Genotyping | Yes |
| HORIMASU (Caucasian)[ | 2014 | Germany | Caucasian | 2002 ATS/ERS consensus statement | 71 | 35 | 51/20 | 15/20 | 67.6 ± 1.2 | 44.3 ± 2.3 | TaqMan SNP Genotyping | Yes |
| Jiang[ | 2015 | China | Asian | 2011 ATS/ERS/JRS/ALAT consensus statement | 187 | 250 | 138/49 | 172/78 | 69.7 ± 4.3 | 67.7 ± 7.3 | Taqman SNP genotyping | Yes |
| JOANNE[ | 2015 | Netherland | Caucasian | 2011ATS/ERS/JRS/ALAT 2001 ATS/ERS consensus statement | 115 | 249 | 97/18 | – | 63.5 ± 11.0 | – | TaqMan SNP genotyping assay | Yes |
| Kishore[ | 2016 | Europe | Caucasian | 2011 ATS/ERS/JRS/ALAT consensus statement | 161 | 96 | 125/40 | 45/51 | 67.97 ± 11.60 | 34.45 ± 8.94 | Sequenom Mass ARRAY | Yes |
| Ley (UCSF)[ | 2017 | USA | Mixed | 2011 ATS/ERS/JRS/ALAT consensus statement | 147 | 503 | – | – | – | – | Taqman SNP Genotyping assay | Yes |
| Ley (UTSW)[ | 2017 | USA | Mixed | 2011ATS/ERS/JRS/ALAT consensus statement | 126 | 503 | – | – | – | – | Taqman SNP Genotyping assay | Yes |
| Noth[ | 2013 | USA | Caucasian | 2000ATS/ERS consensus statement | 1387 | 1367 | 1012/375 | – | 67 (61–73) | – | iPLEX Gold Platform | Yes |
| Peljto(Asian)[ | 2015 | Korean | Asian | 2011 ATS/ERS/JRS/ALAT consensus statement | 239 | 87 | 60/179 | – | 65.1 ± 7.7 | – | – | Yes |
| Peljto(Mexican)[ | 2015 | Mexican | Mixed | 2011 ATS/ERS/JRS/ALAT consensus statement | 83 | 111 | 24/59 | – | 66.0 ± 7.7 | – | – | Yes |
| Seibold[ | 2011 | USA | Caucasian | ATS/ERS/JRS/ALAT consensus statement | 492 | 322 | 352/140 | 147/175 | 67.2 ± 8.1 | 60.3 ± 12.6 | Sequenom iPLEX assays | Yes |
| Song[ | 2021 | China | Asian | 2018ATS/ERS/JRS/ALAT consensus statement | 114 | 100 | 79/35 | 59/41 | 65.13 ± 7.12 | 63.85 ± 6.67 | PCR | Yes |
| Stock[ | 2013 | UK | Caucasian | 2000 2001ATS/ERS consensus statement | 110 | 416 | 79/31 | – | 64.6 (45–85) | – | Taqman SNP Genotyping assay PCR | Yes |
| Stock[ | 2020 | UK | Caucasian | 2000 2001ATS/ERS consensus statement | 23 | 20 | – | – | – | – | Taqman SNP Genotyping assay | Yes |
| Wang[ | 2014 | China | Asian | 2011ATS/ERS/JRS/ALAT consensus statement | 165 | 1013 | 101/64 | 525/488 | 61.78 ± 12.72 | 58.61 ± 12.72 | Taqman SNP Genotyping assay | Yes |
| Wei[ | 2014 | USA | Caucasian | 2001 ATS/ERS consensus statement | 84 | 689 | 55/29 | 360/329 | 64.4 ± 7.7 | 55.7 ± 13.2 | Taqman SNP Genotyping assay PCR | Yes |
| Zhang[ | 2011 | USA | Caucasian | 2001 ATS/ERS consensus statement | 341 | 802 | 238/103 | 436/366 | 67.9 ± 8.8 | 52.7 ± 14.7 | Taqman SNP Genotyping assay | Yes |
ATS American Thoracic Society, ERS European Respiratory Society, JRS Japanese Respiratory Society, ALAT Latin American Thoracic Society, IPF idiopathic pulmonary fibrosis, PCR polymerase chain reaction, SNP Single nucleotide polymorphism, HWE Harwin equilibrium.
Data are mean ± SD, or mean (IQR) or n, unless otherwise stated.
Figure 2The T vs. G model was used to evaluate the correlation between MUC5B gene polymorphism and IPF susceptibility. (a) Forest plot of T vs. G genetic model. (b) Trial sequential analysis of MUC5B polymorphism and IPF risk using the allelic model (T vs. G) (Adjusted Boundaries Print). The combined sample size (N = 32,884) exceeded RIS (N = 26,956), the cumulative Z curve crossed the conventional boundary and the TSA boundary, and the association was established in advance. (c) Inverted funnel chart of T vs. G.
Figure 3The TT vs. GG model was used to evaluate the correlation between MUC5B gene polymorphism and IPF susceptibility. (a) Forest plot of TT vs. GG genetic model. (b) Trial sequential analysis of MUC5B polymorphism and IPF risk using the additive genetic model (TT vs. GG) (Adjusted Boundaries Print). Although the combined sample size (N = 7690) did not exceed RIS (N = 16,994), the cumulative Z curve crossed the conventional boundary and the TSA boundary, and the association was established in advance. (c) Inverted funnel chart of TT vs. GG.
Figure 4The GT vs. GG model was used to evaluate the correlation between MUC5B gene polymorphism and IPF susceptibility. (a) Forest plot of GT vs. GG genetic model. (b) Trial sequential analysis of MUC5B polymorphism and IPF risk using the heterozygous genetic model (GT vs. GG) (Adjusted Boundaries Print). Although the combined sample size (N = 12,737) did not exceed RIS (N = 53,898), the cumulative Z curve crossed the conventional boundary and the TSA boundary, and the association was established in advance. (c) Inverted funnel chart of GT vs. GG.
Figure 5The GT + TT vs. GG model was used to evaluate the correlation between MUC5B gene polymorphism and IPF susceptibility. (a) Forest plot of GT + TT vs. GG genetic model. (b) Trial sequential analysis of MUC5B polymorphism and IPF risk using the dominant genetic model (GT + TT vs. GG) (Adjusted Boundaries Print). Although the combined sample size (N = 13,162) did not exceed RIS (N = 49,050), the cumulative Z curve crossed the conventional boundary and the TSA boundary, and the association was established in advance. (c) Inverted funnel chart of GT + TT vs. GG.
Figure 6The TT vs. GG + GT model was used to evaluate the correlation between MUC5B gene polymorphism and IPF susceptibility. (a) Forest plot of TT vs. GG + GT genetic model. (b) Trial sequential analysis of MUC5B polymorphism and IPF risk using the recessive genetic model (TT vs. GG + GT) (Adjusted Boundaries Print). The combined sample size (N = 11,454) exceeded RIS (N = 11,030), the cumulative Z curve crossed the conventional boundary and the TSA boundary, and the association was established in advance. (c) Inverted funnel chart of TT vs. GG + GT.